A5021453404- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Breast Lesions and Carcinomas
- Radiomics and Machine Learning in Medical Imaging
- Protein purification and stability
- Molecular Biology Techniques and Applications
- Global Cancer Incidence and Screening
- Dialysis and Renal Disease Management
- Renal Transplantation Outcomes and Treatments
- Various Chemistry Research Topics
- Iterative Learning Control Systems
- Cancer Genomics and Diagnostics
- Pharmacological Effects and Toxicity Studies
- Control Systems and Identification
- Gene expression and cancer classification
- Genetic factors in colorectal cancer
- Cell Adhesion Molecules Research
- Hydraulic and Pneumatic Systems
- MRI in cancer diagnosis
The Netherlands Cancer Institute
2018-2024
Dutch Cancer Society
2022
University Medical Center Groningen
2017-2020
University of Groningen
2017-2020
Isala
2019
Erasmus MC Cancer Institute
2019
Amsterdam University Medical Centers
2019
Eindhoven University of Technology
2004
<h3>Importance</h3> Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dual<i>ERBB2</i>(formerly<i>HER2</i>) blockade. <h3>Objective</h3> To evaluate 3-year event-free survival (EFS) and overall (OS) an anthracycline-free anthracycline-containing regimen dual<i>ERBB2</i>blockade in patients stage II III<i>ERBB2</i>-positive breast cancer. <h3>Design, Setting, Participants</h3> A total 438...
Abstract Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or predictive biomarker the context of dual HER2-targeting treatment. In this study, we evaluated association between pathological response (pCR) invasive-disease free survival (IDFS) 389 stage II-III HER2 positive who received anthracycline-containing or...
The objective of this paper is to show how experimentally based modelling can be used for designing Linear Parametrically Varying (LPV) controllers. As a test system we use an industrial pick and place unit with one linear X-drive two independent Ydrives. dynamics the Y-axes depend on Xposition. An LPV model derived by using measured Frequency Response Functions at different positions, fitting parametric each measurement combining these models linking parameters via fit as function operating...
501 Background: The multicenter phase III TRAIN-2 study showed high pathological complete response (pCR) rates after neoadjuvant chemotherapy with and without anthracylines plus dual HER2-blockade in stage II-III HER2-positive breast cancer patients (67% vs 68%, p = 0.95) (NCT01996267). Here we report 3-year efficacy safety outcomes. Methods: Patients were randomly assigned (1:1) to receive 3 cycles 5-fluoruoracil (500mg/m 2 ), epirubicin (90mg/m cyclophosphamide ) followed by 6 paclitaxel...
Dried blood spot (DBS) home sampling allows monitoring creatinine levels and tacrolimus trough as an alternative for in the hospital, which is important kidney transplant patient follow-up. This study aims to assess whether DBS results decreased travel burden lower societal costs.In this single-centre randomized controlled hybrid implementation trial, adult patients were enrolled. The intervention group (n = 25) used on top of usual care first 6 months after transplantation. control 23)...
Background Early detection of colorectal cancer (CRC) is important to achieve better survival. Discriminating symptoms suggestive CRC from benign conditions a challenge for GPs because most known ‘alarm symptoms’ have low predictive values. Aim To further understand the diagnostic process in general practice terms healthcare use and by analysing factors related intervals. Design setting A multimethod approach comprising historical, prospective registry study qualitative content analysis....
Abstract Objectives The aim of this study is to investigate the added value diffusion-weighted imaging (DWI) dynamic-contrast enhanced (DCE)-MRI identify a pathological complete response (pCR) in patients with HER2-positive breast cancer and radiological (rCR). Materials methods This single-center observational 102 stage I-III real-world documented rCR on DCE-MRI. Patients were treated between 2015 2019. Both 1.5 T/3.0 T single-shot echo-planar sequence used. Post neoadjuvant systemic...
Abstract Background The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most benefit. In this study, we determine the prognostic value BluePrint subtyping cancer. Additionally, evaluate its use as a biomarker for predicting to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab. Methods From cohort...
Therapeutic proteins (TPs) are known to be heterogeneous due modifications that occur during the production process and storage. Modifications may also in TPs after their administration patients vivo biotransformation. Ligand binding assays, which widely used bioanalysis of body fluids, typically unable distinguish such modifications. Liquid chromatography coupled mass spectrometry is being increasingly study TPs, but its use biotransformation has been limited until now. We present a novel...
Abstract Background The addition of pertuzumab to trastuzumab containing chemotherapy has boosted pathologic complete response (pCR) rates after neoadjuvant for HER2-positive breast cancer. PCR over 80% have been described and achieving a pCR is associated with favorable long-term outcome. In addition, radiologic (rCR) predictive the in tumors. Therefore it hypothesized that image-guided evaluation based on early occurrence rCR can be used tailor number cycles. Trial design This single arm,...
Abstract Background pCR rates in stage II – III HER2-positive breast cancer have greatly improved since the addition of HER2 targeted agents to neoadjuvant chemotherapy and are associated with excellent long-term survival. While longer treatment regimens increase rate, early complete responses also common. We evaluated an image-guided approach tailor duration based on identification responders. Methods 45 hospitals across Netherlands participated phase 2 TRAIN-3 trial. Patients received...
Abstract BACKGROUND Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy (ET) is an effective strategy to improve progression-free survival (PFS) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). There a lack of comparative data help clinicians decide whether CDK4/6 can best be added first- or second-line ET. The former may provide longer PFS benefit, but associated use the drug, which...
Abstract Background: The addition of pertuzumab to neoadjuvant trastuzumab-containing chemotherapy significantly improves pathological complete response (pCR) rates in patients with HER2-positive breast cancer. However, effects on long-term survival outcomes have been modest. While prior studies suggest that only a subset benefits most from the pertuzumab, reliable biomarker for prediction has not established. BluePrint is an 80-gene molecular subtyping test classifies tumors as Basal-,...
Abstract Background Pertuzumab greatly improves pathologic complete response (pCR) rates in early stage HER2-positive breast cancer. Long-term benefit of pertuzumab, however, is less well established, as follow-up the NEOSPHERE and APHINITY trials did not show clear improvement overall survival, although patients with high risk recurrence (e.g. node positive) appeared to benefit. Since its long-term remains uncertain, we compared outcome treated or without pertuzumab a quasi-random...
Information sources are of tHo broad types, those inten-